Figures & data
Figure 1. Clinical course of the 10 study patients before and after hematopoietic stem cell transplantation. Gilteritinib and quizartinib doses (mg/body) are indicated numerically. AEs were grade 3 or higher and were indicated by letters such as ‘SOS/VOD’. 
(red): diagnosis; 
: CR indicates complete remission; 
: NR, non-remission; 
(yellow): HCT, allogeneic hematopoietic cell transplantation; 
(black): chemo therapy; 
(blue): gilteritinib; fx8(green): quizartinib; 
(orange): AE, adverse event; 
: death, PCP, pneumocystis pneumonia; SOS/VOD, sinusoidal obstructive syndrome/veno-occlusive disease.
Table 1. Patient characteristics from diagnosis to transplantation.
Table 2. Profile of maintenance therapy.
Figure 2. Outcomes of the cohort: (a) overall survival, and (b) disease-free survival starting from transplantation. OS indicates overall survival; DFS, disease-free survival.
Data availability statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.